The effect of an endothelin (ET) A/ETB receptor antagonist, TAK-044, and/or an angiotensin converting enzyme (ACE) inhibitor, temocaprilat, on myocardial metabolism and contraction during ischemia and reperfusion was examined by phosphorus 31-nuclear magnetic resonance (
31P-NMR) in Langendorff rabbit hearts. After normothermic 15 min global ischemia, 60 min of postischemic reperfusion was carried out. TAK-044 and/or temocaprilat was administered from 40 min prior to the global ischemia. Adenosine triphosphate (ATP), creatine phosphate, inorganic phosphate, pH, left ventricular systolic developed pressure (LVDev.P), left ventricular end-diastolic pressure (LVEDP) and coronary flow were measured. Twenty-eight hearts were divided into 4 experimental groups consisted of seven hearts each: Group I consisted of controls, Group II was perfused with TAK-044 (10
-6 mol/L), Group III was perfused with temocaprilat (10
-6 mol/L), and Group IV was perfused with TAK-044 (10
-6 mol/L) in combination with temocaprilat (10
-6 mol/L). Group II showed a more early recovery of ATP during postischemic reperfusion (82±3%) compared with Group I (71±3%). Group III showed a significant inhibition of the decrease in ATP during global ischemia (54±3%) compared with Group I (45 ±3%). Group IV also showed a significant marked inhibition of the decrease in ATP during global ischemia (59±5%) and a more significant improvement on recovery of ATP during postischemic reperfusion (86±3%) compared with the other 3 groups. There were no differences in LVDev.P, LVEDP and coronary flow among these groups. In conclusion, TAK-044 in combination with temocaprilat had a significant potentiation on myocardial metabolism during both ischemia and reperfusion. (
Jpn Circ J 1999;
63: 770 - 774)
View full abstract